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ound embryonic mesenchymal cells have the potential
to differentiate into smooth muscle (SM) cells upon
spreading/elongation (Yang, Y., K.C. Palmer, N.
Relan, C. Diglio, and L. Schuger. 1998. 
 
Development
 
. 125:
2621–2629; Yang, Y., N.K. Relan, D.A. Przywara, and L.
Schuger. 1999. 
 
Development
 
. 126:3027–3033; Yang, Y., S.
Beqaj, P. Kemp, I. Ariel, and L. Schuger. 2000.
 
 J. Clin. Invest.
 
106:1321–1330). In the developing lung, this process is
stimulated by peribronchial accumulation of laminin (LN)-2
(Relan, N.K., Y. Yang, S. Beqaj, J.H. Miner, and L. Schuger.
 
1999.
 
 J. Cell Biol.
 
 147:1341–1350). Here we show that LN-2
stimulates bronchial myogenesis by down-regulating RhoA
activity. Immunohistochemistry, immunoblotting, and reverse
transcriptase–PCR indicated that RhoA, a small GTPase
signaling protein, is abundant in undifferentiated embryonic
mesenchymal cells and that its levels decrease along with
SM myogenesis. Functional studies using agonists and
R
 
antagonists of RhoA activation and dominant positive and
negative plasmid constructs demonstrated that high RhoA
activity was required to maintain the round undifferentiated
mesenchymal cell phenotype. This was in part achieved by
restricting the localization of the myogenic transcription
factor serum response factor (SRF) mostly to the mesenchymal
cell cytoplasm. Upon spreading on LN-2 but not on other
main components of the extracellular matrix, the activity and
level of RhoA decreased rapidly, resulting in translocation of
SRF to the nucleus. Both cell elongation and SRF trans-
location were prevented by overexpression of dominant
positive RhoA. Once the cells underwent SM differentiation,
up-regulation of RhoA activity induced rather than inhibited
SM gene expression. Therefore, our studies suggest a
novel mechanism whereby LN-2 and RhoA modulate
SM myogenesis.
 
Introduction
 
Visceral smooth muscle (SM)* originates from local mesen-
chymal cells that early in midgestation begin to elongate and
synthesize SM proteins (Sawtell and Lessard, 1989; Roman
and McDonald, 1992; McHugh, 1995; Li et al., 1996). Our
studies indicated that this change in cell shape plays an
important role in determining their myogenic fate. Using
different means to control the cell’s shape in cell culture
(Schuger et al., 1996; Yang et al., 1998, 1999; Relan et al.,
1999) and lung organ culture (Schuger et al., 1997; Yang et
al., 2000), we found that essentially all undifferentiated
embryonic mesenchymal cells are potential SM cell precursors
but only undergo SM differentiation upon spreading/
elongation. By contrast, prevention of cell elongation in
vivo and in vitro prevents myogenesis even in mesenchymal
cells that would normally become SM cells (Schuger et al.,
1997; Yang et al., 1998, 1999, 2000; Relan et al., 1999).
Peribronchial mesenchymal cell shape is controlled, at
least in part, by the surrounding extracellular matrix (ECM).
We found that among the ECM components that are
synthesized by the developing lung laminin (LN)-1 and
mainly LN-2 promote bronchial myogenesis by stimulat-
ing peribronchial mesenchymal cell spreading/elongation
(Schuger et al., 1997; Yang et al., 1998; Relan et al., 1999).
LNs are a large family of basement membrane (BM)-related
glycoproteins with important roles in cell adhesion, dif-
ferentiation, and morphogenesis (Colognato and Yurchenco,
2000). LNs are composed of 
 
 
 
, 
 
 
 
, and 
 
 
 
 chains linked together
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by disulfide bonds and are classified by their chain composi-
tion (Burgeson et al., 1994). LN-1 is composed of 
 
 
 
1, 
 
 
 
1,
and 
 
 
 
1 chains, and LN-2 is composed of 
 
 
 
2, 
 
 
 
1, and 
 
 
 
1
chains. LNs along with collagen (CN)-IV and perlecan con-
stitute the main scaffold of all BMs.
In the developing lung, LN-1 synthesis is induced by di-
rect epithelial–mesenchymal interaction (Schuger et al.,
1997). LN-1 is then secreted to the epithelial–mesenchy-
mal interface where it polymerizes, thus contributing to
BM assembly (Schuger et al., 1995, 1996, 1997; Yang et
al., 1998). Round undifferentiated mesenchymal cells use
the developing BM to spread and upon spreading/elonga-
tion begin to both synthesize LN-2 and to undergo myo-
genic differentiation (Relan et al., 1999). The surrounding
mesenchymal cells spread/elongate on the newly deposited
LN-2, differentiating into additional SM cells (Relan et al.,
1999). Absence of functional LN-2 leads to skeletal muscle
dystrophy, cardiomyopathy, and short hypoplastic bron-
chial muscle cells in dy/dy mice (Hillaire et al., 1994; Su-
nada et al., 1994; Xu et al., 1994a,b; Miyagoe et al., 1997;
Relan et al., 1999).
To elucidate the molecular mechanisms that link cell
shape with SM myogenesis, we searched a PCR-based dif-
ferential expression cDNA library created from round un-
differentiated mesenchymal cells subtracted with mesen-
chymal cells undergoing spread-induced SM myogenesis.
The expression of the 
 
rho-a
 
 gene was found to be high in
round undifferentiated mesenchymal cells and to decline
significantly upon cell elongation. RhoA together with
Rac and Cdc42 belongs to a family of small guanidine nu-
cleotide (GTP) binding proteins (GTPases) that plays a
critical role in the organization of the actin cytoskeleton
(Hall, 1998; Bishop and Hall, 2000; Evers et al., 2000).
These proteins cycle between an inactive (GDP-bound)
and active (GTP-bound) conformation in which they in-
teract with specific effector proteins. Active Rho is in-
volved in cell contractility, whereas active Rac and Cdc42
induce extension of lamellipodia and filopodia, contribut-
ing to cell migration (Hall, 1998; Bishop and Hall, 2000;
Evers et al., 2000).
In this study, we show that the activity and level of RhoA in
lung embryonic mesenchymal cells are controlled by LN-2.
More specifically, our data suggest that high RhoA activity is re-
quired to maintain the round undifferentiated mesenchymal
cell phenotype; spreading on LN-2 induces a drastic down-reg-
ulation of both the activation state and level of RhoA, and this
results in cell elongation and irreversible nuclear translocation
of the myogenic transcription factor serum response factor
(SRF). Consistent with previous studies (Takano et al., 1998;
Wei et al., 1998; Mack et al., 2001), we found that once the
Figure 1. RhoA expression and activity decrease during SM differentiation in vitro and in vivo. (A and B) Undifferentiated mesenchymal 
cells isolated from E11 mouse embryonic lungs were cultured for 1 and 18 h. (A) As shown previously (Yang et al., 1999), undifferentiated 
mesenchymal cells undergo spread-induced SM differentiation. This is in part indicated by the expression of SM-related proteins. In contrast, 
 -fetoprotein, an embryonic protein, decreases with myogenic cell differentiation. (B) RT-PCR, Western blot analysis, and immunohistochemistry 
demonstrating rho-a differential expression in embryonic mesenchymal cells undergoing spread-induced SM differentiation in culture. 
Densitometry analysis showed 8.2-, 7.5-, and 11.5-fold decrease in RhoA mRNA, protein, and activity levels, respectively, after 18 h in
culture. No changes were observed in Rac protein levels. Immunohistochemistry, on the bottom left and right, shows high level of cytoplasmic 
RhoA in round undifferentiated mesenchymal cells and weak, almost negative, RhoA immunostaining in a confluent monolayer of spread 
SM-differentiating cells. Notice a single cell that remained round and strongly positive for RhoA. (C) RhoA immunolocalization in mouse 
embryonic lung at days 11 and 14 of gestation. RhoA is diffusely present in the cytoplasm of undifferentiated mesenchymal cells in both
gestational stages, although it is more intense at day 11. The elongated bronchial SM cells (SM) show very weak RhoA immunostaining. The 
small insets represent parallel sections immunostained for SM  -actin to demonstrate absence of SM in E11 lung and its presence in E14 lung. 
Bars: (C) 10  m; (insets) 30  m. 
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cells differentiate into SM RhoA activation stimulates rather
than inhibits myogenesis. Our data provide novel clues on the
mechanism whereby LN-2 regulates SM myogenesis and sug-
gest a surprisingly complex role for RhoA in this process.
 
Results
 
RhoA expression decreased along with
bronchial myogenesis
 
As we showed previously (Yang et al., 1998, 1999), undifferen-
tiated mesenchymal cells from embryonic lungs undergo spon-
taneous SM differentiation upon spreading in culture (Fig. 1
A). Here we used this culture system to generate a PCR-based
cDNA differential expression library to search for potential sup-
pressors of SM myogenesis. Screening of 300 transformed colo-
nies identified the cDNA for RhoA as one of those that was sig-
nificantly more abundant in undifferentiated cells compared
with SM-differentiating cells. Reverse transcriptase (RT)-PCR
analysis, immunoblot, and immunohistochemistry confirmed
that undifferentiated lung mesenchymal cells expressed high
levels of active RhoA and that both the activation state and the
level of RhoA expression decreased rapidly along with SM dif-
ferentiation (Fig. 1 B). Unlike RhoA, the level of Rac remained
constant (Fig. 1 B). Down-regulation of RhoA expression was
confirmed in vivo by immunohistochemical studies performed
on E11 and E14 lung frozen sections (Fig. 1 C). These studies
showed that in the developing lung, RhoA synthesis decreases
in all cells between E11 and E14; however, bronchial SM cells
show the most significant drop in RhoA synthesis (Fig. 1 C).
 
Up-regulation of RhoA activity delayed SM myogenesis
 
Undifferentiated mesenchymal cells were isolated from the
embryonic lung and treated with various agonists and antag-
onists of RhoA activation. The treatments were added before
the cells spread (1 h after plating). Treatment of mesenchy-
mal cell cultures with 1 
 
 
 
M of the agonist endothelin-1
(Fleming et al., 1996) stimulated RhoA activity and delayed
SM-specific gene expression (Fig. 2, A–C). Fig. 2 A demon-
strates that the decrease in RhoA activity normally occurring
in mesenchymal cell cultures undergoing SM differentiation
was prevented in the first hours by endothelin-1 treatment.
These cells remained round for a longer period of time (3–5 h)
and exhibited a significant delay in SM myogenesis as in-
dicated by the lower expression of SM 
 
 
 
-actin, desmin, and
SM-myosin (Fig. 2, B and C). Lysophosphatidic acid (LPA),
another agonist for RhoA activation (Hirshman and Emala,
1999), stimulated RhoA activity, resulting in prolonged cell
rounding and inhibition of SM myogenesis (Fig. 2, D and
E). C3 exoenzyme, an antagonist of RhoA (Leonard et al.,
1992), inhibited RhoA activity in SM-differentiating cul-
tures, and this resulted in stimulation of SM myogenesis
(Fig. 2 F). After 2–3 d in culture, the effect of RhoA activa-
tion on SM gene expression changed from inhibitory to
stimulatory (Fig. 2 G).
 
RhoA modulated SM myogenesis by modulating 
mesenchymal cell shape
 
Undifferentiated mesenchymal cells were isolated from the
lung and transfected with dominant positive (RhoA
 
 
 
) or
dominant negative (RhoA
 
 
 
) hemagglutinin (HA)1-tagged
RhoA plasmid constructs before spreading (1 h after plat-
ing). Transfection of mesenchymal cell cultures with RhoA
 
 
 
kept the cells round and blocked SM myogenesis (Fig. 3 A,
left), whereas transfection of mesenchymal cell cultures with
RhoA
 
 
 
 facilitated spontaneous cell spreading/elongation
(Fig. 3 A, right). The cells expressing RhoA
 
 
 
 remained nega-
tive for SM markers such as desmin (Fig. 3 A, bottom left),
whereas the spread cells differentiated into SM cells as usual
Figure 2. Up-regulation of RhoA activity 
delays SM myogenesis, but once the 
cells are fully differentiated RhoA 
stimulates SM gene expression. 
Undifferentiated mesenchymal cells 
were isolated from E11 mouse embryonic 
lungs, allowed to attach, and cultured 
for up to 8 h in the presence of RhoA 
agonists endothelin-1 and LPA (A–E) or 
in the presence of RhoA antagonist C3 
(F). Additional cells were allowed to 
differentiate for 4 d and were then 
stimulated with endothelin-1 (G). (A) 
The decrease in RhoA activity normally 
occurring in mesenchymal cell cultures 
undergoing spread-induced SM
differentiation is prevented in the first 
hours of culture by 1  M endothelin-1. 
These cultures exhibit a significant delay 
in SM myogenesis as indicated by the 
lower expression of SM  -actin, desmin, 
and SM-myosin mRNA (18 S represents 
the internal control) (B) and protein (C). 
(D) LPA at a concentration of 10  M 
stimulates RhoA activity and as
endothelin-1 also inhibits SM myogenesis (E). (F) 10  M C3 inhibits RhoA activity in the SM-differentiating cultures, and this results in
stimulation of SM myogenesis. (G) Once mesenchymal cells differentiate into SM cells after 4 d in culture (Yang et al., 1999), their response 
to RhoA activation reverses, and then 1  M endothelin-1 stimulates SM gene expression. 
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(Fig. 3 A, bottom right). Overexpression of wild-type RhoA
caused an effect similar to RhoA
 
 
 
 (unpublished data). Ap-
proximately 25–30% of mesenchymal cells in primary cul-
ture were transfected with the RhoA constructs; therefore,
immunoblots showed a corresponding decrease in SM mark-
ers in the cultures transfected with RhoA
 
 
 
 (Fig. 3 B). Since
mesenchymal cells transfected with RhoA
 
 
 
 spread faster
than the nontransfected cells in the same culture, this
resulted in an increase in SM gene expression compared
with controls (Fig. 3 B). Cells transfected with RhoA
 
 
 
 de-
tached relatively more easily; therefore, cultures were lightly
trypsinized for 2 min, and the detached cells were collected
for antitag immunostaining (to confirm selection of trans-
fected cells) and for immunoblot analysis. This enriched
population of RhoA
 
 
 
 cells had total RhoA levels (unpub-
lished data) and activity similar to those found in round un-
differentiated mesenchymal cells (Fig. 3 C) and did not un-
dergo SM myogenesis (Fig. 3 D).
 
Mesenchymal cell spreading on LN-2 induced maximal 
RhoA down-regulation
 
Undifferentiated mesenchymal cells were trypsinized from
embryonic lungs and immediately plated on poly-
 
L
 
-lysine,
CN-I, CN-IV, LN-1, or LN-2 coated onto nontissue cul-
ture dishes. These experiments showed that RhoA levels and
activity decreased in mesenchymal cells spreading on all the
ECM substrata, but the decrease was most marked on LN-2
(Fig. 4 A). Rac levels were not affected (Fig. 4 A). Maximal
cell spreading/elongation was seen on CN-IV followed by
LN-2 (Fig. 4 B). Since cell spreading in itself induces LN-2
synthesis (Relan et al., 1999), 10 
 
 
 
g/ml of anti–LN-2 anti-
body was added to the cultures to block LN-2 (Relan et al.,
1999). Under these conditions, the cells did not spread and
RhoA levels did not decrease (Fig. 4 A). Reprobing of the
membranes with antibodies to SM 
 
 
 
-actin, desmin, and
SM22 indicated that LN-2 represented the best stimulus for
SM myogenesis among the ECM constituents studied (Fig.
4 C). To further test the relationship between LN-2 and
RhoA, we compared the levels of RhoA in lungs from dy/dy,
which express very low levels of functionally active LN-2
(Sunada et al., 1994; Xu et al., 1994a,b). Immunoblot stud-
ies done on three different affected mice and controls dem-
onstrated that dy/dy lungs had significantly higher levels of
RhoA protein (Fig. 4 D) and message (unpublished data).
 
LN-2 down-regulated RhoA activity in the absence of 
cell elongation
 
Cell spreading/elongation was prevented by plating the cells
either on 0.05% poly-
 
L
 
-lysine or on 10-
 
 
 
m diameter culture
microsurfaces (Yang et al., 1999). CN-I, CN-IV, LN-1, and
LN-2 were added to the culture medium once cell attach-
ment was completed (1 h after plating). Under these condi-
Figure 3. Transfection studies with RhoA
  and RhoA
  plasmid constructs, showing that RhoA modulates SM myogenesis by modulating 
mesenchymal cell shape. Undifferentiated mesenchymal cells were isolated from E11 mouse embryonic lungs and transfected with the two 
different RhoA plasmid constructs before spreading (1 h after plating). (A) Cells transfected with RhoA
  and immunostained with anti-HA1 tag 
remain round in shape (top left). Spread nontransfected cells in the same picture cannot be visualized because they are not stained and are in 
a different focus. Round cells do not immunostain for desmin (bottom left; arrow points to one of these cells). In the same picture, note 
desmin-positive spread cells (arrowhead points to one of them). Cells transfected with RhoA
  have spread (top right) and demonstrate strong 
immunopositivity for desmin (bottom right). (B) Immunoblots of cells transfected with RhoA
  and RhoA
 . Mesenchymal cells transfected with 
RhoA
  spread faster than the nontransfected cells in the same culture, leading to an increase in SM gene expression. For comparison, 
mitogen-activated protein kinases show no differences in levels. (C and D) RhoA
 -transfected mesenchymal cells, which detach faster than 
spread nontransfected counterparts, were collected from the cultures by short trypsinization and immediately lysed. (C) After 24 h, cells 
expressing RhoA
  have the same RhoA activity as control undifferentiated mesenchymal cells 1 h after isolation. Here RhoA activity assay 
was run on 3.5  g of protein per lane. (D) Cells expressing RhoA
  do not undergo SM myogenesis as indicated by the absence of SM myosin, 
desmin, and SM  -actin. Note that 3  g protein/lane was loaded for this experiment rather than the 15  g protein loaded in other experiments. 
Thus, the bands seen in the vector control sample are less intense than in other panels. Bar, 20  m. 
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tions, only soluble LN-2 decreased RhoA activity. However,
RhoA levels remained unchanged (Fig. 5 A). Similarly, mes-
enchymal cells plated on 10 
 
 
 
m microsurfaces, to keep cells
round (Yang et al., 1999), showed a reduction in RhoA ac-
tivity without a reduction in RhoA levels upon exposure to
LN-2 (Fig. 5 B). Whether plated on poly-
 
L
 
-lysine or micro-
surfaces, the cells did not undergo myogenesis (unpublished
data). To elucidate whether or not LN-2 had a distinct effect
on focal adhesion kinase (FAK) activation, we performed
immunoblots with three different FAK phosphospecific an-
tibodies. These showed no major differences in FAK phos-
phorylation by the various ECM proteins studied. Actually,
CN-I and CN-IV stimulated FAK phosphorylation slightly
more than LN-1 and LN-2 (Fig. 5 C). When poly-
 
L
 
-lysine
concentration was decreased to the minimal level required to
prevent spontaneous cell spreading in culture (0.01%), only
LN-2 and to a lesser extent LN-1 stimulated mesenchymal
cell spreading/elongation (Fig. 5 D) and down-regulated
RhoA levels (Fig. 5 E). A 10-fold reduction in LN-2 was still
sufficient to induce cell elongation (unpublished data).
 
RhoA activity determined intracellular localization of SRF
 
Immunohistochemical studies showed that SRF is localized
mostly in the cytoplasm of undifferentiated mesenchymal
cells. However, upon spreading/elongation SRF translocates
to the nucleus (Fig. 6 A). SRF translocation does not occur
in undifferentiated mesenchymal cells expressing RhoA
 
 
 
(Fig. 6 A, right). c-myc, another transcription factor present
in these cells, localized to the nucleus of undifferentiated
mesenchymal cells and did not translocate after changes in
cell shape or RhoA activity (unpublished data). Currently,
there is no antibody available that can distinguish between
SRF and its truncated isoform SRF
 
 
 
5. However, the ab-
sence of SRF
 
 
 
5 in RT-PCR analysis of spread/elongated
cells indicated that the nuclear immunoreactivity detected in
these cells represented the full SRF isoform (Fig. 6 B)
 
.
 
 LN-2
or C3 treatments were not sufficient to induce SRF nuclear
translocation in the absence of cell spreading (unpublished
data). Immunohistochemical studies performed on E11 and
E15 embryonic lung sections demonstrated cytoplasmic lo-
calization of SRF in undifferentiated mesenchymal cells
(Fig. 6 C, top) and its nuclear localization in SM-differenti-
ated cells (Fig. 6 C, bottom). Neither forced cell rounding
(Fig. 6 D) nor constitutively active RhoA displaced SRF
back to the cytoplasm (Fig. 6 E). It should be stressed that
we were unable to develop a double immunostaining for
SRF and HA1-tagged RhoA. However, since 
 
 
 
25–30% of
the cells were transfected we should have been able to detect
changes in SRF localization if such changes had taken place.
Screening of 
 
 
 
1,000 cells revealed no cytoplasmic transloca-
tion of SRF after RhoA
 
 
 
 transfection.
 
Discussion
 
RhoA and SM myogenesis
 
We showed previously that undifferentiated mesenchymal
cells from embryonic lungs undergo spontaneous SM differ-
entiation upon spreading in culture (Yang et al., 1998,
1999). Here we used this system to generate a subtracted
cDNA library to search for suppressors of SM myogenesis.
RhoA was identified as a potential candidate because of its
relative abundance in undifferentiated mesenchymal cells.
Figure 4. Mesenchymal cell spreading/
elongation on LN-2 causes maximal 
decrease in the activity and level of 
RhoA and maximal stimulation of SM 
myogenesis. (A) Undifferentiated
mesenchymal cells were isolated from E11 
mouse embryonic lungs and immediately 
plated on 0.05% poly-L-lysine PLL, CN-1, 
CN-IV, LN-1, or LN-2 coated onto
nontissue culture dishes. RhoA levels 
and activity decreased rapidly in
mesenchymal cells spreading on all of 
the ECM substrata and particularly on 
LN-2 but remained high in round cells 
(plated on PLL). Rac levels were not 
affected. Since cell elongation per se
induces LN-2 synthesis in mesenchymal 
cells (Relan et al., 1999), 10  g/ml of 
anti–LN-2 antibody (X-LN-2) were 
added to the cultures to block LN-2
activity (Relan et al., 1999). Under these 
conditions, the cells did not spread and 
RhoA levels did not decrease. (B)
Histogram showing the average length 
achieved by the cells on different 
substrata. UNC, uncoated. Note that 
cells acquired the longest diameters on 
CN-IV rather than LN-2. Nevertheless, 
reprobing the membranes shown in A with antibodies to SM myosin, desmin, and SM22 indicates that LN-2 represents the best stimulus for 
SM myogenesis among the ECM constituents studied (C). (D) RhoA levels in lungs from three dy/dy mice and three matched control animals, 
showing that dy/dy lungs have significantly higher levels of RhoA. The bottom panels show staining of the blots with Coomassie blue to 
demonstrate equal protein loading in each set of dy/dy and control lungs. 
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RT-PCR, immunoblotting, immunohistochemistry, and ac-
tivity assays confirmed the rapid decrease in RhoA levels and
activity upon SM myogenic differentiation. Down-regula-
tion of RhoA expression during bronchial myogenesis was
confirmed in vivo by immunohistochemistry.
Functional studies indicated that the differential expression
of RhoA plays a critical role in regulating SM myogenesis.
Treatment of round undifferentiated mesenchymal cells with
RhoA agonists endothelin-1 and LPA delayed SM-specific
gene expression and prolonged cell rounding. In contrast, C3
exoenzyme, an antagonist of RhoA, caused the opposite effect.
Interestingly, once the mesenchymal cells acquired syn-
thetic and electrical properties of mature SM cells, which
happens after 2–3 d in culture (Yang et al., 1999), the ef-
fect of RhoA activation on SM gene expression changed
from inhibitory to stimulatory. These last data are consis-
tent with previous studies, which linked RhoA activity
with stimulation of muscle-specific gene expression in
muscle cells and myofibroblasts (Takano et al., 1998; Wei
et al., 1998; Mack et al., 2001). In these cells, the effect of
RhoA activation depends upon stress fiber formation (Ta-
kano et al., 1998; Wei et al., 1998; Mack et al., 2001).
However, another study showed that cytochalasin D,
which disrupts stress fiber formation, activates RhoA in fi-
broblasts (Ren et al., 1999). Similarly, Laufs et al. (2000)
found that the actin cytoskeleton exerts a negative feed-
back regulation on 
 
rho
 
 gene transcription in endothelial
cells. Therefore, the effect of the cytoskeleton on RhoA ac-
tivity seems to vary depending on the cell type. It may be
critical that stress fibers are not well developed in undiffer-
entiated mesenchymal cells and mesenchymal cells under-
going SM differentiation (this can be appreciated from the
phalloidin stains presented in Fig. 6). This lack of stress fi-
bers may explain why RhoA activity is high in SM cell pre-
cursors compared with mature SM cells, which have a well-
developed actin cytoskeleton.
 
Cell shape, RhoA, and SM myogenesis
 
Since endothelin-1 and LPA also act through signaling path-
ways other than RhoA (Swarthout and Walling, 2000), we
used RhoA
 
 
 
 and RhoA
 
 
 
 plasmid constructs to further eval-
uate the involvement of RhoA in the process of SM myogen-
Figure 5. LN-2 down-regulates RhoA 
activity in the absence of cell elongation. 
Undifferentiated embryonic mesenchymal 
cells were isolated from E11 mouse 
embryonic lungs and plated on
poly-L-lysine (A, D, and E) or on 10- m 
diameter culture microsurfaces (Yang et 
al., 1999) (B). CN-I, CN-IV, LN-1, LN-2, 
or no ECM (no-M) were added to the 
culture medium once cell attachment 
was completed (1 h after plating). (A) 
Cells plated on 0.05% poly-L-lysine, 
showing that soluble LN-2 decreases 
RhoA activity. Note that RhoA levels
remain unchanged. (B) Mesenchymal 
cells plated on 10  m microsurfaces also 
showing a reduction in RhoA activity 
without a reduction in RhoA levels upon 
exposure to LN-2. (C) Immunoblots with 
three different FAK phosphospecific 
antibodies, showing that LN-2 elicits 
low FAK phosphorylation compared 
with other ECM constituents. (D)
Poly-L-lysine was reduced to 0.01% 
(minimal level required to prevent 
spontaneous cell spreading). Under 
these conditions, LN-2 and to a minimal 
extent LN-1 stimulate mesenchymal cell 
spreading/elongation. (E) LN-2– and 
LN-1–induced mesenchymal cell 
elongation results in down-regulation of 
both RhoA activity and level.
 
Figure 6.
 
In undifferentiated and immature mesenchymal cells, RhoA activity determines the intracellular localization of SRF. 
 
(A) 
Undifferentiated mesenchymal cells were isolated from E11 mouse embryonic lungs and allowed to undergo spread-induced SM differentiation. 
Some of the cultures were transfected with RhoA
 
 
 
 before spreading (1 h after plating). Cells were immunostained for SRF 1, 6, and 18 h after 
plating. In undifferentiated mesenchymal cells, SRF is localized mainly in the cytoplasm (arrow in first panel points to cytoplasm). SRF translocates 
to the nucleus along with SM differentiation (arrow in second panel points to a cell with nuclear and cytoplasmic SRF, and arrow in third 
panel points to nuclear SRF). SRF translocation does not occur in undifferentiated mesenchymal cells expressing RhoA
 
 
 
 (right, arrow points to 
cytoplasm). In same figure, notice presence of SRF in nuclei of spread untransfected cell (arrowhead). Phalloidin stain for F-actin (red) and 
DAPI stain (blue) are shown to respectively highlight the cytoplasm and nucleus and thereby facilitate interpretation of the figure. (B) RT-PCR 
shows presence of SRF and SRF
 
 
 
5 in undifferentiated mesenchymal cells, presence of SRF but not SRF
 
 
 
5 in spread cells 8 h after plating, and 
presence of both in RhoA
 
 
 
-transfected cells
 
.
 
 (C) Immunohistochemical studies performed on E11 and E15 embryonic lung sections, revealing 
cytoplasmic localization of SRF in undifferentiated mesenchymal cells in vivo (top, arrow points to cytoplasm) and its nuclear localization in  
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SM-differentiated cells in vivo (bottom, arrow points to nucleus). n, nucleus; c, cytoplasm. (D) Undifferentiated mesenchymal cells were cultured 
for either 1 or 24 h. The cells were then trypsinized, replated on poly-
 
L
 
-lysine, and cultured for another 18 h. At the end of the second culture 
period, the cells were immunostained for SRF. Although cells replated on poly-
 
L
 
-lysine after 1 h in regular culture still have most SRF 
immunoreactivity in the cytoplasm (left; c, cytoplasm), cells that were allowed to spread for 24 h before replating on poly-
 
L
 
-lysine have all 
SRF immunoreactivity in the nucleus (right; n, nucleus). (E) Spread SM-differentiating mesenchymal cells transfected with RhoA
 
 
 
 or vector 
alone and immunostained with anti-HA1 tag by immunoperoxidase (top) or with anti-SRF by immunofluorescence (bottom). Immunostaining 
for SRF shows no translocation of SRF to the cytoplasm. Notice that although we were unable to develop a double immunostaining for SRF 
and HA1-tagged RhoA, since 
 
 
 
25–30% of the cells were transfected we should have been able to detect scattered cells with changes in SRF 
localization if such changes had taken place. Bars, 10 
 
 
 
m. 
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esis. Transfection of mesenchymal cell cultures with consti-
tutively active RhoA (RhoA
 ) or wild-type RhoA kept the
cells round and blocked SM myogenesis, whereas expression
of RhoA
  facilitated spontaneous cell spreading/elongation
and SM differentiation as usual.
Therefore, these studies suggested that high RhoA activity is
required to maintain a round undifferentiated mesenchymal
cell phenotype, whereas a decrease in RhoA facilitates cell
elongation and subsequent SM myogenesis. Previous studies
have shown already that high RhoA activity may cause cell
rounding. The best example is represented by neurons and
neuroblastoma cells in which RhoA activity also causes neurite
retraction (Katoh et al., 1996; Postma et al., 1996; Tigyi et al.,
1996; Kozma et al., 1997). However, our studies are the first
to indicate that RhoA may play a decisive role in determining
the differentiation fate of embryonic cells through the control
of the cell shape.
LN-2 and RhoA
Since cells require ECM to spread/elongate, we determined
the effect of some of the main ECM constituents on mesen-
chymal cell spreading/elongation. CN-I was selected because
it represents the main non-BM ECM component, CN-IV
and LN-1 because they are major BM components, and LN-2
because it is the main LN in muscle BMs (Vachon et al.,
1996). In addition, our previous studies indicated the impor-
tance of LN-2 in bronchial myogenesis (Relan et al., 1999).
Poly-L-lysine was used to promote cell attachment without
spreading (Yang et al., 1998, 1999; Relan et al., 1999). These
experiments showed that RhoA levels and activity decreased in
mesenchymal cells spreading on all the ECM substrata but the
decrease was most marked on LN-2. Immunoblot analysis in-
dicated that LN-2 was also the best stimulus for SM myogen-
esis, supporting our previous findings.
Despite the fact that LN-2 induced maximal RhoA down-
regulation, cell spreading/elongation occurred at least the
same on CN-IV, indicating that the effect of LN-2 on RhoA
was not correlated directly with cell length. Since cell spread-
ing in itself induces LN-2 synthesis (Relan et al., 1999), we
added LN-2 blocking antibodies (Relan et al., 1999) to the
cultures. Under these conditions, the cells did not spread and
RhoA levels did not decrease, demonstrating the important
role of LN-2 in inducing embryonic mesenchymal cell spread-
ing/elongation. However, studies in which cells were forced to
remain round while being exposed to LN-2 showed that LN-
2-induced down-regulation of RhoA was insufficient to stim-
ulate myogenesis. Therefore, these additional studies demon-
strated that cell spreading/elongation is the dominant factor in
promoting SM myogenesis.
Dy/dy mice express very low levels of functionally active
LN-2 due to a spontaneous genetic mutation that results in
a truncated LN  2 chain. This deficiency in active LN-2
leads to muscular dystrophy (Sunada et al., 1994; Xu et al.,
1994a,b). On histological examination, bronchial SM cells
in dy/dy mice are shorter than control animals and express
less SM-specific protein (Relan et al., 1999). Supporting
our in vitro data, immunoblot studies done on three differ-
ent affected mice and controls demonstrated that dy/dy
lungs had significantly higher RhoA levels. Nevertheless,
we were surprised by the magnitude of this difference, and
part of our current effort is directed to further understand
this system.
Several other ECM molecules have been shown to mod-
ulate the activity of GTPases (Giancotti and Ruoslahti,
1999). Fibronectin was the first identified and the best stud-
ied so far. Fibronectin activates RhoA while inhibiting
Cdc42 and thereby supports growth factor-stimulated cell
cycle progression (Bourdoulous et al., 1998; Danen et al.,
2000). Our ongoing studies seem to suggest that although
mesenchymal cells spread on fibronectin, they maintain rela-
tively high RhoA levels and show delayed SM differentia-
tion. Interestingly, a similar positive and negative regulation
of SM gene expression by LN and FN has been shown in
adult vascular SM cells (Thyberg and Hultgardh-Nilsson,
1994). We are currently trying to determine whether the
differences between LN-2 and fibronectin are related to
their ability to organize the cell’s cytoskeleton. In addition to
the effects of fibronectin and LN-1 and -2 to modulate GTP-
ase activity, it has been shown recently that tenascin-C sup-
presses fibronectin-induced RhoA activation (Wenk et al.,
2000) and thrombospondin-1 stimulates fascin spikes by ac-
tivating Rac and Cdc42 (Adams and Schwartz, 2000).
Therefore, these studies underline the importance of the
ECM in controlling GTPase function.
RhoA and SRF cytoplasmic/nuclear translocation
The myogenic transcription factor SRF is a member of the
MADS (MCM-1, agamous, and deficiens and SRF) box
family of transcription factors. SRF binds to the CArG box
or CArG box–like motif, an essential cis element present in
muscle-specific proteins, such as SM  -actin, SM22, SM
myosin,   -tropomyosin, and caldesmon, and stimulates
their transcription (Belaguli et al., 1997; Kim et al., 1997;
Browning et al., 1998). SRF has several truncated isoforms,
which originate by alternative splicing from the same pre-
mRNA (Belaguli et al., 1999; Kemp and Metcalfe, 2000).
Our previous studies indicated that undifferentiated mesen-
chymal cells synthesize SRF and SRF 5 isoforms but lose
SRF 5 early during SM myogenesis (Yang et al., 2000).
This change is of functional relevance because SRF 5 inhib-
its SM myogenesis (Yang et al., 2000).
In this study, we found that SRF immunoreactivity is local-
ized mostly in the cytoplasm of undifferentiated mesenchymal
cells. However, upon spreading/elongation SRF translocates
to the nucleus. SRF translocation does not occur in undiffer-
entiated mesenchymal cells expressing RhoA
 , indicating the
involvement of RhoA in this process. The absence of SRF 5
in RT-PCR analysis of spread/elongated cells indicated that
the nuclear immunoreactivity detected in these cells repre-
sented the full SRF isoform. LN-2 or C3 treatments were not
sufficient to induce SRF nuclear translocation in the absence
of cell spreading, suggesting a critical role for cell spreading/
elongation in stimulating SRF nuclear translocation.
A similar pattern of SRF cytoplasmic/nuclear transloca-
tion was observed previously during skeletal muscle differ-
entiation (Croissant et al., 1996). These investigators
found that SRF has cytoplasmic localization in undiffer-
entiated myoblasts but becomes enriched in nuclei of dif-
ferentiated myotubes. In most cells, however, xSRF seems
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shown to translocate to the cytoplasm during prophase
(Gauthier-Rouviere et al., 1995) and after prolonged se-
rum deprivation in culture (Camoretti-Mercado et al.,
2000). The cytoplasmic/nuclear translocation of SRF ob-
served during myogenesis may serve a critical develop-
mental function by contributing to the initiation of SM
myogenesis when the right conditions are established.
During the developmental time that SRF is enriched in
the cytoplasm, the low levels of SRF detected in the nu-
cleus (Fig. 6 A) may still be sufficient to ensure transcrip-
tion of nonmyogenic SRF-responsive genes, such as c-fos
and   -actin. Alternatively, since SRF-responsive genes
also have binding sites for other transcription factors, such
as AP-1 for  -actin and AP-2 for c-fos, their transcription
may be controlled by the latter rather than by SRF
(Berkowitz et al., 1989).
A common mechanism for intracellular translocation of
proteins, including transcription factors, involves their phos-
phorylation/dephosphorylation (Nakabeppu and Nathans,
1989; Metz and Ziff, 1991; Norris and Manley, 1992). Al-
though SRF has several phosphorylation sites (Fluck et al.,
2000), we were unable to detect differences in SRF phosphor-
ylation during its cytoplasmic/nuclear translocation (unpub-
lished data). Interestingly, maintenance of high RhoA activity
by RhoA
  transfection prevents the disappearance of SRF 5
isoform as shown in Fig. 6 B. Since SRF 5 has the ability to
dimerize with SRF and thereby cause inhibition of SM gene
transcription (Belaguli et al., 1999), we are currently investi-
gating the possibility that SRF 5 may hinder SRF nuclear
translocation by dimerizing with SRF in the cytoplasm.
It has been established previously that RhoA activity stim-
ulates SRF-dependent transcription in several cell types, in-
cluding mature SM cells and terminally differentiated car-
diomyocytes (Hill et al., 1995; Wei et al., 1998, 2001b;
Sotiropoulos et al., 1999; Mack et al., 2001). In accordance
with these reports, here we have found that mesenchymal
cells reverse their response to RhoA upon myogenic differen-
tiation. Furthermore, two recent papers have shown that ac-
tive RhoA can either inhibit (Wei et al., 2001a) or stimulate
(Lu et al., 2001) myogenesis in different developmental
models. Together, these data plus previously discussed pa-
pers (Katoh et al., 1996; Postma et al., 1996; Tigyi et al.,
1996; Kozma et al., 1997; Ren et al., 1999; Laufs et al.,
2000) seem to support the concept that RhoA may serve dif-
ferent and even opposite functions, depending on the cell
type, shape, cytoskeleton, and/or differentiation status.
Based on the studies presented here, we propose that during
lung development high RhoA activity contributes to mainte-
nance of mesenchymal cell rounding and thereby restricts SRF
mainly to the cytoplasm, where it cannot activate SM gene tran-
scription. Then gradual peribronchial accumulation of LN-2
and to a lesser extent LN-1 results in RhoA down-regulation
and incipient cell spreading. This change in cell shape leads to
further stimulation of LN-2 production, additional decrease in
RhoA activity, further cell spreading, and eventually SRF trans-
location to the nucleus. All of these factors contribute to the in-
duction of SM myogenesis. Furthermore, we also propose that
higher RhoA activity in the nonperibronchial areas may be one
of the mechanisms put in place to maintain mesenchymal cells
undifferentiated until new cues are set to allow the emergence
of nonmuscular cell lineages.
Materials and methods
Construction of libraries and subtracted probe
Undifferentiated mesenchymal cells were isolated from E11 mouse lungs
by differential plating as described previously (Schuger et al., 1997; Yang
et al., 1998, 1999). The cells were cultured for either 1 or 18 h, the first
time point representing undifferentiated embryonic mesenchymal cells
and the second representing cells undergoing SM differentiation. The
mRNA from the two cultures was amplified using the SMART
® cDNA syn-
thesis kit (CLONTECH, Laboratories, Inc.), and PCR-Select
® (CLONTECH,
Laboratories, Inc.) was then used for subtractive hybridization. Briefly, two
pools of RsaI-digested cDNA from undifferentiated cells were used as
tester and ligated to two different oligonucleotide adapters. RsaI-digested
cDNA from differentiated SM cells was used as driver without adapters.
Two hybridizations were performed between the tester population and ex-
cess driver. Only the cDNAs with different adapters at both ends were PCR
amplified and produced a pool of cDNA fragments more abundant in the
undifferentiated than in the differentiated cells. The subtracted cDNAs
were cloned into a pGEM-T vector (Promega) and transformed into Esche-
richia coli. 300 transformed colonies were selected randomly for screening.
Dot-blot hybridization was performed with 
32P-labeled cDNA forward-
and reverse-subtracted cDNAs as probes. The reverse-subtracted probe
was made by subtractive hybridization performed with the original tester
cDNA as a driver and the driver cDNA as a tester.
Cell culture
Crl:CD-1 (ICR) BR mice (Charles River Laboratories) were mated, and the
day of finding a vaginal plug was designated as day 0 of embryonic devel-
opment. Undifferentiated mesenchymal cells were isolated from E11 or E12
lungs as described previously (Schuger et al., 1997; Yang et al., 1998, 1999)
and immediately plated on uncoated tissue culture dishes or on nontissue
culture dishes coated with various substrata. These included CN-I, CN-IV,
LN-1 (all from Collaborative Biomedical Products), LN-2 (Life Technology),
and poly-L-lysine (Sigma-Aldrich). The nontissue culture dishes were coated
for 3 h with 10  g of each ECM protein dissolved in 1 ml of PBS, or poly-
L-lysine (Sigma-Aldrich) at concentrations of 0.05 or 0.01% wt/vol, also in 1
ml of PBS. Poly-L-lysine was used to obtain cell attachment without spread-
ing (Yang et al., 1998, 1999, 2000; Relan et al., 1999). The dishes were
then washed with PBS and allowed to dry before use. Alternatively, the
cells were plated on poly-L-lysine–coated dishes, and the various ECM con-
stituents were added at the described concentrations to the culture medium
immediately after cell attachment was completed (1 h). In some experi-
ments, the concentration of LN-2 added to the medium was reduced by 10-
fold (1  g/ml). Cell shape was additionally controlled by plating the cells on
10- or 20- m diameter culture microsurfaces (Relan et al., 1999; Yang et
al., 1999), the first to force cell rounding and the second to allow cell
spreading/elongation (Yang et al., 1999). The cells were cultured in MEM
with 10 or 0.5% FCS for different time periods for up to 24 h. Our previous
studies showed that 0.5% FCS arrests mesenchymal cell proliferation (Yang
et al., 1999). At the end of the culture period, the cells were used for immu-
nohistochemical studies or lysed for RNA and protein analysis.
Cell treatments
To increase RhoA activity, embryonic mesenchymal cells were treated
with 1  M of endothelin-1 (Sigma-Aldrich) (Fleming et al., 1996) or 10  M
lysophosphatidic acid (Sigma-Aldrich) (Hirshman and Emala, 1999). To re-
duce RhoA activity, embryonic mesenchymal cells were treated with 10
 g/ml of C3 exoenzyme (Calbiochem) after being permeabilized with 75
 g/ml of saponin for 3 min (Leonard et al., 1992). In some experiments,
10   g/ml of blocking anti–LN-2 antibody (Alexis Biochemicals Corp.)
(Relan et al., 1999) was added to the cultures after cell attachment was
completed (1 h after plating). After treatment, cells were lysed and ana-
lyzed by immunoblotting for RhoA and SM markers.
Immunoblot analysis
Cell cultures and lungs from adult C57BL/6J dy/dy mice and C57BL/6J
 / 
normal mice (both from Jackson ImmunoResearch Laboratories) were lysed
and resolved by SDS-PAGE. Western blots were done using standard proto-
cols. Rabbit polyclonal antibody to RhoA (Santa Cruz Biotechnology, Inc.)
and mouse monoclonal antibody to RhoA (Santa Cruz Biotechnology, Inc.)
were each used at a concentration of 1  g/ml. Mouse monoclonal antibody
against Rac (Upstate Biotechnology) was used at a concentration of 0.5  g/
ml. Mitogen-activated protein kinases (ERK1 and ERK2) were detected us-
ing rabbit polyclonal antibody (Zymed Laboratories) at a concentration of
0.5  g/ml. As in previous studies (Relan et al., 1999; Yang et al., 1999,
2000), the following antibodies were used for detection of SM-specific pro-
teins: a mouse monoclonal antibody to SM  -actin (Boehringer) at a con-902 The Journal of Cell Biology | Volume 156, Number 5, 2002
centration of 0.25  g/ml, a mouse monoclonal antibody to desmin (Dako)
at a concentration of 1.125  g/ml, rabbit polyclonal antibodies to SM-myo-
sin (Biomedical Technologies) at a concentration of 10  g/ml, rabbit poly-
clonal antibodies to SM22 (provided by Dr. Rodrigo Bravo, Bristol-Myers
Squibb Pharmaceutical Research Institute, Princeton, NJ) at a concentration
of 0.2  g/ml, and mouse monoclonal antibodies to HA1 tag (Santa Cruz
Biotechnology, Inc.) at a concentration of 0.125  g/ml. Anti-FAK pY
861,
pY
397, and pY
925 phosphospecific antibodies (Biosource International) were
used at concentrations of 1.0, 0.36, and 0.75  g/ml, respectively. Primary
antibodies were detected with HRP-conjugated secondary antibody diluted
1:3,000 (Bio-Rad Laboratories). The bands were visualized by chemilumi-
nescence using a commercial kit (Amersham Life Sciences) according to
the manufacturer’s instructions. In some experiments, the membranes were
stripped of primary and secondary antibodies (Mattingly et al., 2001) and
reprobed with new antibodies as described above.
Immunohistochemistry
Mesenchymal cell cultures and 5- m thick frozen sections cut from E11 and
E14 embryonic lungs were fixed for 5 min in 100% ethanol and immu-
nostained for RhoA and SRF (tissue sections) and RhoA, SRF, and desmin (cell
cultures) following published protocols (Yang et al., 1998). Antibodies to SRF
were purchased from Santa Cruz Biotechnology and used at a concentration
of 8  g/ml. Rabbit polyclonal antibody to RhoA was used at a concentration
of 8  g/ml, and antibody against desmin was used at a concentration of 20  g/
ml. After incubation with the first antibody, the samples were exposed to a
1:50 dilution of biotin-conjugated goat anti–mouse or biotin-conjugated anti–
rabbit IgG (Sigma-Aldrich). Cell staining was completed using a commercial
peroxidase-antiperoxidase kit following the manufacturer’s instructions (ABC
kit; Vector Laboratories). Cell cultures were also immunostained for SRF using
a FITC-conjugated secondary antibody (Molecular Probes) at a 1:100 dilution.
The cells were examined with a ZEISS Laser (LSM) 310 confocal microscope.
Cytoplasmic and nuclear staining
F-actin (cytoplasm) was stained using rhodamine-phallotoxin (Molecular
Probes). After fixation with 4% paraformaldehyde solution for 10 min, the
mesenchymal cells were preincubated with 2% BSA dissolved in PBS with
0.1% Tween for 30 min. The cells were then stained with 5 U/ml of phal-
lotoxin for 20 min. To highlight nuclei, cells and tissue sections were incu-
bated for 5 min with 5  g/ml of DAPI (Molecular Probes) dissolved in wa-
ter after blocking with 2% BSA.
Transient transfections
Vectors encoding wild-type RhoA, dominant negative RhoA, mutated at resi-
due 19 to replace threonine with asparagine (termed N19), and an active mu-
tant of RhoA, which has a mutation of valine in place of glycine at residue 14
(termed V14), were constructed by subcloning BamHI-EcoRI fragments into
pKH3 (Mattingly et al., 1994). This plasmid, which includes a cytomegalovirus
promoter/enhancer and SV40 origin of replication, attaches an in-frame triple
HA1 tag to the NH2 terminus of the inserts. Thus, the HA13RhoA(N19) and
HA13RhoA(V14) proteins that are produced can be immunorecognized by an
anti-HA1 antibody (Santa Cruz Biotechnology). As described previously (Yang
et al., 1999), primary cultures of mesenchymal cells were transfected 1 h after
attachment was completed using lipofectamine plus reagent (Life Technology)
following the manufacturer’s instructions. The plasmids or vector without in-
sert, used as control, were mixed with the lipofectamine reagent in a 1:3.5 wt/
vol proportion, and the cells were transfected for 4 h in the presence of 10%
FBS. After 4 h of incubation at 37 C, the transfection medium was replaced
with fresh 10% MEM, and the cultures were incubated for an additional 16–
18 h. Immunohistochemical studies using anti-HA1 antibody indicated that
 25–30% of the cells in our primary cultures were efficiently transfected.
RhoA activity assay
GTP-bound RhoA (active RhoA) was affinity isolated from cell lysates based
on the capability of GST-rhotekin to bind to GTP-Rho (Ren et al., 1999). The
assay was performed on mesenchymal cell cultures following the manufac-
turer’s instructions (Upstate Biotechnology). Briefly, the cells were lysed with
Rho-binding lysis buffer (50 mM Tris, pH 7.2, 1% Triton X-100, 0.5% sodium
deoxycholate, 0.1% SDS, 500 mM NaCl, 10 mM MgCl2 with 10  g/ml of leu-
peptin, 10  g/ml of aprotinin, and 1 mM PMSF). Lysates were cleared by cen-
trifugation, and active RhoA was precipitated with 20  g of a GST-tagged fu-
sion protein corresponding to residues 7–89 of mouse rhotekin Rho binding
domain expressed in E. coli and bound to agarose beads. The precipitates
were washed three times in washing buffer (50 mM Tris, pH 7.2, 1% Triton
X-100, 150 mM NaCl, 10 mM MgCl2, 0.1 mM PMSF, 10  g/ml aprotinin, and
10  g/ml leupeptin), and the bound proteins were eluted and resolved in 14%
polyacrylamide gels, transferred to nitrocellulose membranes, and immuno-
blotted with 1  g/ml of rabbit polyclonal antibody to RhoA.
RT-PCR
Mesenchymal cell cultures were washed with PBS, and total RNA was ex-
tracted with Trizol (Life Technology). RT-PCR was performed with the Gene-
Amp RNA PCR kit (PerkinElmer) following the manufacturer’s instructions.
The following primers were used for PCR: RhoA, 5  forward primer, 5 -agcct-
catgcggttaatttg-3  and 3  reverse primer 5 -tctttgaattagcgcctggt-3 ; SM  -actin,
5  forward primer, 5 -tccctggagaagagctacga-3  and 3  reverse primer, 5 -
gggcttttaatctccttcgg-3 ; desmin, 5  forward primer, 5 -gtgaagatggccttggatgt-3 
and 3  reverse primer, 5 -gtagcctcgctgacaacctc-3 ; SM-myosin, 5  forward
primer 5 -gacaactcctctcgctttgg-3 ; and SRF isoforms, 5  forward primer 5 -
atcaccaactacctggcacc-3  and 3  reverse primer 5 -cacctgtagctcggtgaggt-3 . All
amplifications shown here represent the product of 25 cycles except for SM
myosin, which is shown at 30 cycles. A primer pair (Ambion Inc.) was used to
produce a 488 base pair 18S ribosomal amplicon as an internal control. Un-
der the conditions used in these studies, plateau of internal control and most
amplicons was reached at 35 cycles.
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